Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07433-4Source: DataRank Database

The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system is a research paper published in Breast Cancer Research and Treatment (2024). On theSindex it has a DataRank of 0.359. It has been cited 7 times, with 3 citing works in its 1-hop citation network.

N/A

0.359DataRank · unranked

Scored on demand from live citation data

Open Access7 citations · 3 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)Impact (FWCI 1.27)OA: greenTopics (44)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 87%Citation Network 13%

Base Score Contribution

0.312

From this paper's citation signal

Citation Network Contribution

0.0471

From 1 citing papers with measurable signal

Learn more about DataRank methodology →

Top 3 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 3 citers.

A phenotype-independent “label-capture-release” process for isolating viable circulating tumor cells in real-time drug susceptibility testing
The Innovation202515 citations50 referencesContributes 0.055
Nanomedicine: A Dual Approach to Diagnosis and Therapy
20260 citations232 referencesContributes 0.000
Impact of Hormonal Therapy Regimens and Adverse Drug Reactions on Quality of Life in Breast Cancer Patients at Dr. Moewardi Regional General Hospital, Surakarta
Sciences of Pharmacy20260 citations47 referencesContributes 0.000

Authors (23)

Kelli O’Connell ORCID,Sonia Persaud ORCID,Victoria Blinder ORCID,Rachael Burganowski,Isaac J. Ergas ORCID

Live enrichment

PubMed:39150586 PMC:PMC12045552 OpenAlex:https://openalex.org/W4401643929

National Cancer Institute of the National Institute of Health, United States

Grant: R50CA211115

National Cancer Institute of the National Institute of Health, United States

Grant: U24CA171524

National Cancer Institute

Grant: P01CA154292

NCI NIH HHS

Grant: U01 CA195565

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: R37 CA222793

National Institutes of Health

Grant: 5U24CA171524-03

CRN4: Cancer Research Resources & Collaboration in Integrated Health Care Systems

National Institutes of Health

Grant: 7R50CA211115-02

Group Health Cancer Research Program Research Specialist Award

National Institutes of Health

Grant: 5R37CA222793-04

Obesity, chemotherapy dosing, and breast cancer outcomes

National Institutes of Health

Grant: 2P01CA154292-11

Advancing Equitable Risk-based Breast Cancer Screening and Surveillance in Community Practice

National Institutes of Health

Grant: 1U01CA195565-01A1

Infrastructure for Pathways, a Prospective Study of Breast Cancer Survivorship

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

Geoffrey Beene Cancer Research Center

FWCI

1.27

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

greenLicense: Springer Nature TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12045552/pdf/nihms-2063324.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s10549-024-07433-4.pdf

publisherhttps://link.springer.com/article/10.1007/s10549-024-07433-4/fulltext.html

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12045552/

Fields of Study

Breast Cancer Treatment StudiesCancer Treatment and PharmacologyEconomic and Financial Impacts of Cancer03 medical and health sciences0302 clinical medicine

MeSH Terms

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCaliforniaFemaleHumansMiddle AgedNeoplasm StagingPractice Guidelines as TopicDelivery of Health Care, IntegratedGuideline Adherence

Keywords

MedicineBreast cancerOncologyRegimenInternal medicineDocetaxelGuidelineTrastuzumabCyclophosphamideCancerChemotherapyGynecologyPathologyClinical Practice PatternsAdherence GuidelineAdultDelivery of Health Care, IntegratedBreast NeoplasmsMiddle AgedCaliforniaAntineoplastic Combined Chemotherapy ProtocolsPractice Guidelines as TopicHumansFemaleGuideline AdherenceNeoplasm StagingAged

Sustainable Development Goals

SDG 0: Good health and well-being